D-0982-2022 Class III Terminated

Recalled by Novartis Pharmaceuticals Corporation — East Hanover, NJ

Recall Details

Product Type
Drugs
Report Date
June 15, 2022
Initiation Date
May 10, 2022
Termination Date
February 28, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,187,092 vials

Product Description

Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

Reason for Recall

Failed Impurities/Degradation Specifications.

Distribution Pattern

Nationwide within the United States

Code Information

Lot #:a) and b) 20E21, 20E22, 20E53, 20E54, 20E95, 20E96, 20ED1, 20ED2, 20ED3, 20EK1 Exp. Date 4/2023; 20F27, 20F28, 20F66, 20F67,20FH6, Exp. Date 05/2023; 20G47, 20G48, 20G49, 20G57, 20GB8, 20GE5, 20GE6, Exp. Date 06/2023; 20M41, 20M42, 20M56, 20M66, 20M67, 20MA4, Exp. Date 07/2023; 20S20, 20S22, 20S44, 20S94, Exp. Date 10/2023; 20SA6, 20SA7, 20SE0, Exp. Date 10/2023, 20TE2, 20TG5, Exp. Date 11/2023.